Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

PHASE2UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

June 30, 2006

Conditions
AutismAutistic DisorderChild Development Disorders, PervasiveGastrointestinal DiseasesSigns and Symptoms, Digestive
Interventions
DRUG

Oralgam (human immunoglobulin)

Trial Locations (22)

14642

Strong Center for Developmental Disabilities, University of Rochester Medical Center, Rochester

15203

Merck Child Outpatient Clinic, Pittsburgh

32607

Sarkis Clinical Trials, Gainesville

32608

University of Florida HSC, Gainesville

32763

Medical Research Group of Central Florida, Orange City

32901

International Child Development Resource Center, Melbourne

40291

Bluegrass Clinical Research, Louisville

43210

Nisonger Center Ohio State University, Columbus

44308

Children's Hospital Medical Center of Akron, Akron

46202

Riley Hospital for Children, Indianapolis

48073

Pivotal Research Centers - Detroit, Royal Oak

63141

Mercy Health Research, St Louis

66160

University of Kansas Medical Center, Developmental Disabilities Center, Kansas City

70808

Gulf Coast Research, LLC, Baton Rouge

78217

North San Antonio Healthcare Associates, San Antonio

85006

Southwest Autism Research and Resource Center, Phoenix

85012

Center for Autism Research and Education, Phoenix

95817

University of California Davis, MIND Institute, Sacramento

98109

Autism Spectrum Treatment and Research Center, Seattle

02043

Hardy Health Associates, Hingham

08854

Robert Wood Johnson Medical School, Piscataway

45229-3039

Cincinnati Children's Hospital, Cincinnati

Sponsors
All Listed Sponsors
lead

PediaMed Pharmaceuticals

INDUSTRY

NCT00110708 - Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism | Biotech Hunter | Biotech Hunter